News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Duolingo posts robust profits and growth, while Zeta Global leverages AI for enterprise marketing, but each faces distinct risks and valuation profiles.
For investors weighing entry points, the bifurcation between the fundamental demand story and near-term sentiment risk is the central tension. On the bull side, the component suppliers enjoy a structural advantage: unlike finished-goods robot makers, they are not wedded to a single OEM's commercial success. A gearbox from Harmonic Drive or a motor from Nidec can go into a Tesla Optimus, a Figure robot, or a Unitree platform interchangeably, which diversifies revenue risk and amplifies upside if
Ouster's Rev8 compliance, record revenue growth, physical AI push and debt-free balance sheet support its rally to a 52-week high.
A one-time $986 million tariff recovery drove most of the EPS and margin beat
Shares of Tesla (NASDAQ:TSLA) have been picking up in recent sessions, now close to 13% in just three sessions. Undoubtedly, just because Space Exploration Technologies (NASDAQ:SPCX) is the new hot Elon Musk stock in town does not mean shares of the EV juggernaut are going to be stuck going sideways for a while longer. With ... Tesla’s Chip Breakthrough Is a Big Deal. Time to Buy the Surge?
Investor interest in the broader space sector is reignited. Planet Labs PBC rallied over 15% after Rocket Lab announced its $8 billion acquisition of Iridium Communications.
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside […]
Over the past six months, NXP Semiconductors has been a great trade, beating the S&P 500 by 19.4%. Its stock price has climbed to $282.96, representing a healthy 27.9% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Micron and Sandisk are still great buys.
Analysts at Wedbush gave SpaceX an "outperform" rating with a price target of $190 a share. The stock rose 2% on Wednesday morning.
Cathie Wood over at Ark Invest has been making moves in recent months amid the barrage of volatility slamming the tech sector. Undoubtedly, semiconductors have continued to be the leadership group while the Magnificent Seven have pulled the brakes a bit. With the flagship Ark Innovation ETF (ARKK) trailing the markets, up just over 3%, ... Cathie Wood’s Palantir Buy Might Be a Signal to Buy the Dip
Investing.com -- RBC Capital Markets downgraded Dow to Sector Perform from Outperform and cut its price target to $28 from $51, saying recent gains in polyethylene prices are likely to prove short-lived while the company's multibillion-dollar Alberta petrochemicals project will continue to strain cash flow.
Kroger is buying regional grocer and pharmacy retailer Giant Eagle in a deal valued at $1.65 billion. Giant Eagle, which is privately held, has 197 supermarkets and 11 standalone pharmacies across northern Ohio, western Pennsylvania, West Virginia, Maryland and Indiana. Kroger has thousands of stores operating under various brands, including Ralphs, King Soopers, Smith’s and Fred Meyer.
Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) is one of the Iran Peace Deal Sends Oil Lower: Top 8 Travel Stocks to Buy Now. On June 16, Citi raised the firm’s price target on Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) to $25 from $21 and reiterated a Buy rating. The firm believes that after the Iran […]
Tenable (TENB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
With shares of Elon Musk’s rocket and AI company volatile in post-IPO trading, investors will be paying close attention to what Wall Street has to say about valuation. The latest rating is a bullish call, valuing SpaceX at a cool $2.5 trillion. Wedbush analyst Dan Ives launched coverage of SpaceX with a Buy rating and a $190 price target on Tuesday evening.
SonoTek (SOTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Regal Rexnord (RRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
MU's AI-driven memory surge fuels a historic rally, making semiconductor ETFs a diversified way to tap the industry's broad-based momentum.
NBIX, MYRG, XYZ, DK and DY show strong relative price strength, upbeat estimate revisions and solid fundamentals heading into the second half.
Holders are hurting, and relief might take awhile to arrive.
MT begins the second tranche of its 2025-2030 share buyback after completing the first, with plans to repurchase up to 10 million more shares.
The thesis is straightforward: SpaceX (NASDAQ:SPCX) gets added to the Nasdaq-100 on July 7, and every index fund, ETF and benchmark-tracking pension on the planet has to buy it whether they like the valuation or not. That is mechanical demand against a float that has been public for 11 trading days, and it is the ... Here’s a Massive Reason You Should Buy SpaceX Before July 7th
The three chipmakers are now the 10th, 11th, and 12th most valuable U.S. tech companies as investors broaden AI bets
Guggenheim upgraded Salesforce to Buy from Neutral, setting a $228 price target on the stock, according to TheFly.
History suggests software stocks are poised for a rebound
Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?